ANIX:NSD-Anixa Biosciences Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 3.10

Change

0.00 (0.00)%

Market Cap

USD 0.09B

Volume

0.09M

Avg Analyst Target

USD 11.00 (+254.84%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Anixa Biosciences Inc (ANIX) Stock Analysis:
Based on the Anixa Biosciences Inc stock forecasts from 1 analysts, the average analyst target price for Anixa Biosciences Inc is USD 11.00 over the next 12 months. Anixa Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Anixa Biosciences Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Anixa Biosciences Inc’s stock price was USD 3.10. Anixa Biosciences Inc’s stock price has changed by -0.31% over the past week, -0.08% over the past month and -26.37% over the last year.

About

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-23 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

N/A

USD57.20B 59.90 43.56
IDXX IDEXX Laboratories Inc

N/A

USD42.87B 57.99 51.35
ICLR ICON Public Limited Company

N/A

USD20.08B 85.73 50.57
EXAS Exact Sciences Corporation

N/A

USD12.86B N/A N/A
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
SYNH Syneos Health Inc

N/A

USD8.97B 36.31 22.53
GH Guardant Health Inc

N/A

USD7.31B N/A N/A
MEDP Medpace Holdings Inc

N/A

USD5.96B 34.35 32.22
NTRA Natera Inc

N/A

USD5.93B N/A N/A
QDEL Quidel Corporation

N/A

USD4.38B 5.09 4.30

ETFs Containing ANIX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.38% 100% A+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.38% 100% A+ 94% A
Trailing 12 Months  
Capital Gain -26.37% 74% C 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.37% 74% C 36% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 12.78% 42% F 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.78% 42% F 56% F
Risk Return Profile  
Volatility (Standard Deviation) 61.66% 51% F 27% F
Risk Adjusted Return 20.73% 42% F 38% F
Market Capitalization 0.09B 25% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.72 61% D- 44% F
Price / Cash Flow Ratio -18.92 90% A- 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -61.02% 27% F 18% F
Return on Invested Capital -60.35% 31% F 14% F
Return on Assets -35.92% 13% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.27 62% D- 36% F
Short Percent 2.61% 69% D+ 50% F
Beta 1.67 24% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector